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Abstract
The effectiveness of stem cell mobilization with granulocyte colony-stimulating factor (G-CSF) in 
lymphoma patients is suboptimal. We reviewed our institutional experience using 
chemomobilization with etoposide (VP-16; 375mg/m2 on days +1 and +2) and G-CSF (5ug/kg 
twice daily from day +3 through the final day of collection) in 159 patients with lymphoma. This 
approach resulted in successful mobilization (> 2 × 106 CD34 cells collected) in 94% of patients 
(83% within 4 apheresis sessions). 57% of patients collected at least 5 × 106 cells in ≤ 2 days and 
were defined as good mobilizers. The regimen was safe with a low rate of rehospitalization. 
Average costs were $14,923 for good mobilizers and $27,044 for poor mobilizers (p<0.05). Using 
our data, we performed a ‘break-even’ analysis that demonstrated that adding two doses of 
Plerixafor to predicted poor mobilizers at the time of first CD34 count would achieve cost 
neutrality if the frequency of good mobilizers were to increase by 21%, while the frequency of 
good mobilizers would need to increase by 25% if three doses of Plerixafor were used. We 
conclude that chemomobilization with etoposide and G-CSF in patients with lymphoma is 
effective, with future opportunities for cost-neutral improvement using novel agents.
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Autologous stem cell transplantation (ASCT) is a potentially curative strategy in the 
management of patients with Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma 
HL) who have relapsed disease.1 The ability to undergo ASCT depends upon the successful 
mobilization and collection of stem cells.
G-CSF alone mobilization strategies have the advantage of convenience in scheduling 
apheresis procedures and sparing of significant side-effects. In lymphoma populations, 
however, many patients mobilize inefficiently with this strategy. In a recent phase III trial, 
only 47% of NHL patients mobilized with G-CSF alone collected ≥ 2 × 106 CD34 cells.2 In 
a retrospective review of 656 lymphoma patients mobilized with G-CSF alone, 14% did not 
proceed to apheresis and 30% of those who proceeded to apheresis required four or more 
sessions to achieve a minimum of 2 × 106 CD34 cells/kg.3
The addition of chemotherapy to G-CSF improves stem cell yield and mobilization 
outcomes. In a study of chemomobilization with cyclophosphamide, 68% of lymphoma 
patients collected ≥ 2 × 106 CD 34 cells with a median of 1 apheresis days.4 Heizmann and 
colleagues investigated the use of vinorelbine with G-CSF and found that 96% of patients 
successfully collected sufficient stem cells for ASCT, with a median yield of 3.6 × 106 
CD34 cells.5 Copelan et al. found that 50/55 patients who received full dose etoposide 
(2g/m2) and G-CSF with or without rituximab as part of a prospective study collected at 
least 2 × 106CD34 cells and proceeded to ASCT.6 A larger, retrospective, multi-institutional 
analysis showed that in comparison to patients receiving G-CSF alone, patients who 
received etoposide 2g/m2 in addition to G-CSF had a higher CD34 cell yield ( 9.34 × 106 vs. 
3.83 × 106) and a higher rate of adequate collection after 2 days (42% vs 16%).7 Concerns 
with chemomobilization include the potential for febrile neutropenia, tMDS/AML, and 
unpredictable timing of collection.
Mozobil (Plerixafor; Genzyme Corporation, Cambridge, MA) is a small molecule that 
interferes with the binding of stromal cell-derived factor-1a (SDF-1a) with CXC chemokine 
receptor 4 (CXCR4). In a large phase III study in NHL, the addition of plerixafor to G-CSF 
led to significantly more patients collecting > 5 × 106 CD34 cells in ≤4 days than G-CSF 
alone (59% vs 20%). Recent data demonstrate the feasibility of adding plerixafor to 
conventional chemomobilization regimens.8 Multiple studies have identified “poor 
mobilizers” or “failed mobilizers” who experience increased costs and complications 
relative to “good mobilizers,”4,9 even if overall post-transplant outcomes are not necessarily 
inferior.10 However, it is not clear if plerixafor and G-CSF should replace 
chemomobilization altogether, or if plerixafor should be integrated into “just in time” or 
“salvage” strategies in order to improve mobilization outcomes in a cost-neutral way.11-14 
We have previously reported on our experience with chemomobilization using an 
intermediate intensity etoposide regimen that has led to effective collection of CD34 cells in 
patients with multiple myeloma.15 Here, we report our institutional experience with 
etoposide-based chemomobilization in lymphoma patients, and we propose a rational way in 
which plerixafor might be integrated into a chemomobilization strategy for selected patients.
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This analysis included patients between the ages of 19 and 75 who received mobilization 
with VP-16 and G-CSF prior to ASCT for NHL or HL at our institution between June 2004 
and September 2010. The mobilization regimen consisted of placement of a central 
apheresis catheter followed by outpatient administration of intravenous VP-16 (375 mg/m2) 
once daily on days +1 and +2. Patients received ondansetron 24mg orally and 
dexamethasone 20mg orally 30 minutes prior to each VP-16 infusion, as well as 
prochlorperazine 10mg every 4 hours for nausea or emesis. Each VP-16 infusion was diluted 
to a concentration of 0.4mg/mL and infused over 4 hours, followed by a 20-mL post-
infusion saline flush. G-CSF was administered at a dose of 5 ug/kg twice daily starting on 
day +3 and continuing through the last day of stem cell collection. Antimicrobial 
prophylaxis was given concurrently using levofloxacin 500mg orally once daily to all 
patients starting on day +5. Peripheral blood CD34+ cell counts were checked starting on 
day +12, except for circumstances in which patients were noted to have white blood counts 
within the normal range or greater than the upper limit of normal at the time of routine 
monitoring at a pre D+12 office visit. Apheresis was initiated when the peripheral blood 
CD34+ cell count was ≥7/uL,16 and all patients had stem cells collected between days +7 
and +13. Target volumes were calculated based on an algorithm that includes the patient’s 
weight in kilograms, the peripheral pre-collection CD34+ count, and the requested cell dose 
(usually a minimum of 5 × 106 CD34+ cells/kg and a target of 8 × 106 CD34+ cells/kg; 
however, some patients collecting between 5 × 106 CD34+ cells/kg and 8 × 106 CD34+ 
cells/kg did not attempt further days of collection, according to physician preference). All 
collections were done using the COBE Spectra machine (CaridianBCT, Lakewood, CO). 
Platelet transfusions were administered routinely for platelet counts ≤10,000, with higher 
thresholds used for patients at a higher risk for clinically significant bleeding.
Efficacy, Safety, and Cost Data
Cell yields, other clinical endpoints, and complication data were abstracted from medical 
records by chart review. A small number of patients had missing values of baseline platelet 
and white blood cell (WBC) counts (n=4 and 5, respectively); missing values in platelet and 
WBC count values were imputed with their respective arithmetic means. Inpatient 
admissions were tabulated and analyzed using University of North Carolina hospital data 
and chart review for outside hospitalizations. Data on costs were analyzed for all patients. 
Individualized costs were identified on a per-patient basis and included all non-drug and 
drug charges. Non-drug charges included catheter insertion, infusion, laboratory draws, 
provider visits, apheresis procedures, cryopreservation, blood and platelet transfusions, and 
inpatient admission charges if necessary. These costs were derived from institutional billing 
data. For chemotherapeutic agents and supportive medications, average wholesale price 
(AWP) was determined from the Redbook 2010 edition. AWP was adjusted to average sales 
price (ASP) using the calculation: ASP = AWP – (AWP × 0.2), reflecting an estimated 20% 
margin of difference.
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Total mobilization related costs were separated by the phase of mobilization and also 
included unexpected health service utilization. Expected costs included medications 
(chemotherapy, G-CSF, oral antibiotics), mobilization services (catheter placement, 
chemotherapy infusion), laboratory testing (complete blood counts, peripheral blood CD34 
count), and collection services (collection, cryopreservation and storage). Unexpected health 
service utilization costs were also identified by detailed chart review of each participating 
patient, as well as communication with outside facilities if needed to clarify clinical 
documentation. These unexpected costs included inpatient hospital stays, platelet and red 
blood cell transfusions, additional laboratory testing, and intravenous antibiotics.
Statistical Methods
Descriptive statistics were performed on baseline data. “Good mobilizers” were defined as 
those patients who collected ≥5 × 106/kg CD34+ cells in ≤2 days of collection, and “poor 
mobilizers” were defined as everyone else. Average costs associated with 
chemomobilization were compared between “good” and “poor” mobilizers using Wilcoxon 
rank-sum tests. Medians (with range) for the patient characteristics and means (with 
standard deviation) for cost categories are reported. Predictive probabilities of being a good 
vs. poor mobilizer at the time of the first peripheral CD34 testing were determined using 
multivariate logistic regression analysis. Clinically relevant covariates were controlled for in 
the model; these included age at transplant, gender, time since diagnosis, duration of prior 
chemotherapy, number of prior chemotherapy regimens, baseline WBC and baseline platelet 
counts. Average costs were then calculated for new groups of predicted good and poor 
mobilizers. Break-even analyses were performed under several hypothetical scenarios that 
included the use of plerixafor. Only significant scenarios have been presented in this paper.
All statistical analyses were performed using SAS© v 9.2 (Cary, NC) at an a priori 
significance level of 0.05.
Results
Patients
A total of 159 patients with lymphoma underwent stem cell mobilization and collection with 
VP-16 and G-CSF between June 2004 and September 2010. 26 patients received rituximab 
375mg/m2 on day +1 for reasons related to enrollment on clinical trials or physician 
preference. Median age of the sample was 52 years, and more than half of patients were 
male (62 percent). The median age at the time of transplant was 52 years, with a range of 19 
to 75 years. Patients had received an average of 7.5 months of prior chemotherapy (range: 
2.5-31 months), with 25 patients (16%) having received 1 prior treatment regimen, 89 (56%) 
having received 2 prior regimens, 31 (19%) having received 3 prior lines of therapy, and 
14(9%) having received at least 4 prior regimens in addition to the etoposide mobilization 
regimen described here.
Efficacy
Ninety-four percent of all patients (150/159, 94%) were able to collect successfully (> 2 × 
106 CD34+ cells/kg) after 1 mobilization, with 8 patients (5%) requiring a second 
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mobilization or bone marrow harvest and 1 patient not proceeding to transplant. 83% of 
patients achieved successful collection within 4 apheresis days. Patients hospitalized 
elsewhere for neutropenic fevers returned to the transplant center for successful collection. 
Patients with positive blood cultures received a minimum of 48 hours of antibiotics and 
must have been afebrile at the time of apheresis. Using our definition of “good mobilizers” 
(ability to collect at least 5 × 106 cells/kg in 1-2 days), 57% (n=90) of patients were good 
mobilizers. Median CD34 cells/kg collected for the entire population was 6.2 × 106, though 
this number was nearly twice as large in the good vs. poor mobilizing group (8.5 × 106 vs 
4.4 × 106). The median number of apheresis days in the entire population was 2, though this 
was substantially smaller among good mobilizers (median 1 day) vs. poor mobilizers 
(median 4 days). 109 (70%) of all patients and 82 (91%) of all good mobilizing patients 
were able to initiate apheresis on or before D+12.
Safety
Most patients underwent at least 1 interim blood count assessment at our institution during 
the course of mobilization, usually around D+8, with the rest having blood counts checked 
at outside institutions. 50 (31%) of patients required at least one PRBC transfusion (14% of 
good mobilizers and 54% of poor mobilizers), and 51 (32%) required at least one platelet 
transfusion (14% of good mobilizers and 55% of poor mobilizers). Over half of the poor 
mobilizing patient population required PRBC or platelet transfusions. Ten patients (6%) 
required inpatient admission during the mobilization period, mostly for febrile neutropenia. 
These included 2 (2%) of good mobilizers and 8 (12%) of poor mobilizers. There was one 
case of treatment-related myelodysplasia in a patient who received etoposide mobilization 
and a BEAM autograft for T cell lymphoma. Cases of tMDS were determined by detailed 
chart review and long-term follow-up data collection by the transplant center. Efficacy and 
safety data are presented in Table 1.
Costs
For all patients, the average total cost of chemomobilization was $20,184 (SD, $8,485). The 
average cost of chemotherapy ($2,371) represented 12% of these total costs, whereas other 
costs related to mobilization, apheresis, product processing and storage were significantly 
greater ($15,373). Costs varied markedly between poor and good mobilizers, including costs 
of unexpected health services utilization beyond the apheresis and cytokines (transfusions, 
admissions and additional antibiotics), which were over three times greater in poor 
mobilizers ($3,804 vs. $1,396). Overall, total average costs for poor mobilizers were nearly 
twice as high as for good mobilizers ($27,045 vs $14,924, p<0.05). Cost data are presented 
in Table 2.
Predictive modeling
In order to identify predictors of good and poor mobilizers, we performed a logistic 
regression analysis including baseline data as well as the first peripheral blood CD34 count 
(obtained between D+9 and D+15, with 82% of first counts obtained on D+12). In this 
model, both a lower first peripheral blood CD34 count (p<0.001) and a lower pre-
chemotherapy platelet count (p=0.024) were found to be statistically significantly associated 
with poor mobilization. For simplification, we ran a third logistic model using the first 
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peripheral blood CD34 count alone and found that the first peripheral blood CD34 count 
was the single most important predictor of good vs. poor mobilization (c-statistic of 0.94), 
and a cutoff point of an absolute CD34 count of 27/μL in the peripheral blood differentiated 
good from poor mobilizers. Estimates from this multivariate logistic model are presented in 
Table 3.
Using these data, we performed analyses under five hypothetical scenarios that incorporated 
the use of plerixafor (Table 4). For each of these scenarios, we assumed an average sales 
price for plerixafor of $6000/dose, and a median number of either 3 doses of plerixafor 
(based on the intervention arm in the phase III trial of plerixafor + G-CSF in NHL patients)2 
or 2 doses of plerixafor. We compared all groups to our current average costs of $20,184 per 
patient. Under these hypothetical scenarios, we found that only when plerixafor was given to 
predicted poor mobilizers (based on peripheral blood CD34 count) would predicted costs 
approximate our current costs, and thus become cost-neutral. In general, cost-neutrality is 
achieved when an intervention results in savings that are equal to the cost of the 
intervention, and thus does not increase overall costs. We used this concept of cost-
neutrality to determine the desired minimum effectiveness of plerixafor by converting 
enough patients from the poor mobilizing to good mobilizing category to bring down overall 
resource utilization and offset the costs of plerixafor. If 3 doses of plerixafor were given to 
predicted poor mobilizers, 62% of these patients would need to become good mobilizers to 
achieve cost neutrality, whereas 49% of predicted poor mobilizers would need to become 
good mobilizers if a median of 2 doses of plerixafor were used. Assumptions underlying 
these models accompany Table 4.
Table 5 displays the relative contribution of each mobilization component to total costs 
under the hypothetical scenarios in which two or three doses of plerixafor were given to 
predicted poor mobilizers.
Discussion
The optimal method for mobilizing patients prior to ASCT for lymphoma remains unclear. 
Success rates using G-CSF alone are suboptimal, with only 20% of patients in the G-CSF 
alone control arm of a large Phase III study collecting 5 × 106 CD34 cells within 5 days. 
Plerixafor has been found to improve outcomes relative to G-CSF alone (59% of patients in 
the plerixafor group vs 20% in the G-CSF group met the primary endpoint in the phase III 
study) but is costly and still results in a significant percentage of patients with suboptimal 
CD34+ cell collections. Though chemomobilization is well-established, this technique 
comes with risks. We therefore sought to investigate the effectiveness of chemomobilization 
and to identify cost-effective opportunities for improvement in the current era of plerixafor.
Krishnan et al. reported that chemomobilization with high doses of etoposide (2g/m2 in 
51/62 patients, and either 1g/m2 or 1.5g/m2 in 9 other patients) was associated with a 12.3 
fold increased risk of developing t-AML with 11q23/21q22 abnormalities.17 At our 
institution, we have therefore used lower dose etoposide (375mg/m2 × 2 days) in addition to 
G-CSF as part of a chemomobilization strategy prior to ASCT in an attempt to gain the 
benefits of chemomobilization without an increased risk of t-MDS or AML. We have 
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previously demonstrated this approach to be highly effective in patients with multiple 
myeloma; among 152 patients with multiple myeloma mobilized in this fashion, 100% of 
patients successfully mobilized with 99% collecting at least 5 × 106 CD34 cells/kg in 1-2 
days (“good mobilizers”).15 In the current study, we looked at the effectiveness of this 
regimen among patients with lymphoma, and although our results were promising (94% 
achieved successful collection), the proportion of “good mobilizers” (57%) was substantially 
less than in the myeloma study. Further, we demonstrated that poor mobilizers consumed 
significantly greater resources and incurred substantially higher costs than good mobilizers, 
consistent with published data.18
Though direct comparisons are unwarranted, as ours was not a randomized study and 
baseline characteristics among the patient populations may have varied, Table 6 suggests 
that our results are at least comparable, from an efficacy standpoint, to other mobilization 
strategies. The CD34 stem cell yield with VP-16 chemomobilization (6.4 × 106) appears 
similar to the yield from the plerixafor arm in the Dipersio study (5.7 × 106) and better than 
the G-CSF alone arm (1.98 × 106). Likewise, the percentage of patients collecting at least 2 
× 106 CD34 cells/kg or 5 × 106 CD34 cells/kg in ≤ 4 apheresis days appeared similar in our 
study to the published plerixafor data.
Limitations of chemo-mobilization regimens include short and long term safety concerns of 
incorporating even intermediate dose chemotherapeutic agents into the mobilization 
regimen. Indeed, 30% of patients in our study required red blood cell transfusions, 30% 
required platelet transfusions, and 12% required inpatient admission, mostly for neutropenic 
fevers. However, much of this resource utilization was driven by poor mobilizers, over half 
of whom needed transfusions and nearly 20% of whom required inpatient hospitalization 
during the mobilization period. Costs of mobilization in general were also twice as large in 
poor mobilizers compared to good mobilizers, with a substantial range of costs in the poor 
mobilizing population (average cost $27044, St. Dev. $8099).
Thus, a logical strategy to improve upon our results would involve intervening in the case of 
poorly mobilizing patients, particularly given recent data demonstrating efficacy of 
plerixafor in G-CSF mobilized patients with low preapheresis peripheral blood CD34 
counts.19 Towards this end, we developed a predictive model based primarily on the first 
peripheral blood CD34 count. Identifying a cutoff point of 27/μL, we found that the first 
peripheral blood CD34 count predicted good vs poor mobilizers with favorable test 
characteristics. Further, we constructed a hypothetical scenario in which cost neutrality 
could theoretically be achieved by adding plerixafor to the mobilization regimens of patients 
with an initial peripheral blood CD34 count of less than 27.
Our study has several limitations. First, data were obtained by chart review and tus may 
have missed resource utilization data points that could have affected the subsequent 
predictive models. Thus, resource utilization data were reviewed by more than one reviewer, 
including the entire electronic medical record (outpatient and inpatient notes, transfusion 
labs, administered blood products, and external communication). Second, although 82% of 
first peripheral blood CD34 counts were obtained on D+12, the date of first peripheral blood 
CD34 count acquisition was not uniform. Third, there remains a relative paucity of 
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published data about the expected efficacy of incorporating plerixafor into 
chemomobilization regimens. Whether 49% of a predicted poor mobilizing population 
treated with chemomobilization can be reasonably expected to convert to good mobilizers, 
as was required in our breakeven model, is not clear. Published data suggest encouraging 
efficacy in this setting so this may be a reasonable hypothesis to test.20-22 Finally, we did not 
include the highly variable costs associated with rescue strategies for failed mobilizations, 
which limited our ability to make total resource and cost comparisons for strategies (such as 
G-CSF alone) in which failed mobilizations would be expected to comprise a substantial 
proportion of the patient population.
Though about a third of patients did require transfusion support, and a small number 
(especially poor mobilizers) required inpatient hospitalization, there were no treatment-
related deaths and only one identified case of treatment related MDS, showing that this 
regimen is safe. Our modeling suggests that an alternative strategy of planned plerixafor and 
G-CSF for all patients is not likely to be cost effective. Moving forward, we plan to conduct 
a prospective trial with a further reduction in the etoposide dose, as well as administration of 
plerixafor to predicted poor mobilizers, to determine if the efficacy and safety of our 
regimen can be further improved in a cost-neutral way.
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Table 1




















11 (7-29) 10 (7-11) 13 (11-29)
Number of patients
initiating apheresis on
or before Day 12 (%)
109 (70) 82 (91) 27 (39)
Mean CD34# on first
day tested














10 (6) 2 (2) 8 (12)
Number of patients
requiring at least one
PRBC transfusion
(%)
50 (31) 13 (14) 37 (54)
Number of patients
requiring at least one
platelet transfusion
(%)




19 (12) 7 (8) 12 (17)
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Table 2
Costs Associated with Chemomobilization among good and poor mobilizers
Parameter All









Average cost of mobilization /




















Average cost of unexpected



















Based on the Wilcoxon Rank-sum Tests













Wood et al. Page 13
Table 3








First CD34* 1.112 1.070 - 1.176 <.0001
Age at Time of Mobilization 1.012 0.960 - 1.067 0.6616
Gender 1.535 0.459 - 5.134 0.4867
Time Since Diagnosis 0.994 0.969 - 1.020 0.6747
Duration of Prior
Chemotherapy
0.849 0.673 - 1.072 0.1688
Number of Prior
Chemotherapy Regimens
1.022 0.332 - 3.150 0.9698
Receipt of Rituxan 0.257 0.060 - 1.096 0.0663
WBC at Mobilization 1.329 0.980 - 1.802 0.0670
Platelet Count at
Mobilization*
1.007 1.001 - 1.013 0.0249
*
indicates significant variable at p<0.05
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Table 4

































B) G-CSF + plerixafor 159(100%) 78 (49%) n/a $32,760 $12,576





(3 doses for all) (breakevennot possible)
D) VP-16/G-CSF + plerixafor
69 (43%) 131 (82%)
62%
$20,228 $44(3 doses for predicted poor
mobilizers) (breakeven)







(2 doses for all) (breakevennot possible)
F) VP-16/G-CSF + plerixafor
69 (43%) 124 (78%)
49%
$20,233 $49(2 doses for predicted poor
mobilizers) (breakeven)
A. All patients receive etoposide and G-CSF, with efficacy rates, costs and complications calculated from our observed cohort.
B. All patients receive G-CSF (7 total days) and 3 doses of plerixafor, 3 days of apheresis, no levofloxacin, no etoposide, no PRBC transfusions, no 
Platelet transfusions, no IV antibiotics, no inpatient admissions. Median doses of plerixafor, median days of apheresis, and efficacy rates are 
extrapolated from published phase III data.2
C. All patients receive etoposide and G-CSF. Median 3 doses of plerixafor are given to all patients. This scenario assumes a 100% efficacy rate in 
converting bad to good mobilizers. Average costs/pt based on costs associated with patients who are good mobilizers + 3 doses of plerixafor for 
each patient.
D. All patients receive etoposide and G-CSF. Median 3 doses of plerixafor are given to predicted poor mobilizers based on first CD34 count. A 
breakeven analysis is performed by modeling the # of patients who would need to experience improved outcomes and thus lower resource 
utilization in order to offset the costs of giving plerixafor to these patients. Please see Table 7 for component costs.
E. All patients receive etoposide and G-CSF. Median 2 doses of plerixafor are given to all patients. This scenario assumes a 100% efficacy rate in 
converting bad to good mobilizers. Average costs /pt based on costs associated with patients who are good mobilizers + 2 doses of plerixafor for 
each patient.
F. All patients receive etoposide and G-CSF. Median 2 doses of plerixafor are given to predicted poor mobilizers based on first CD34 count 
(probability ≤0.5). A breakeven analysis is performed by modeling the # of patients who would need to experience improved outcomes and thus 
lower resource utilization in order to offset the costs of giving plerixafor to these patients. Please see Table 5 for component costs.













Wood et al. Page 15
Table 5





Average cost of treatment with VP-16/G-
CSF + 3 doses plerixafor for predicted
poor mobilizers (Scenario D)
Average cost of treatment with VP-16/G-
CSF + 2 doses plerixafor for predicted
poor mobilizers (Scenario F)
Good Poor Total Good Poor Total
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Table 6
Comparison of Efficacy of Chemomobilization with Published Phase III Data










Median total CD34+ cells ×
106/kg N (range)





collecting ≥5 × 106CD34+
cells/kg in ≤ 2 apheresis
days (%)
89 (55.9%) 21 (14.2%) 74 (49.1%6)15
Number of patients
collecting ≥2 × 106CD34+
cells/kg in ≤ 4 apheresis
days (%)





151 (95%) 66 (45%) 135 (90.0%)
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